Short answer
ANAVEX LIFE SCIENCES CORP. (AVXL) filed an 8-K current report with the SEC on August 25, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Q3 fiscal 2026 financial results for quarter ended June 30, 2026.
ANAVEX LIFE SCIENCES CORP. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 fiscal 2026 financial results for quarter ended June 30, 2026
- Press release issued August 25, 2026, with detailed results in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 FY2026 cash $118.3M, up from $102.6M, projected to fund operations into mid-to-late FY2028
- Q3 net income $7.8M, or $0.08 per share, driven primarily by $17.4M of reversed stock-based compensation
- Alzheimer’s data submitted to FDA IND, supporting planned U.S. discussions on Phase 3 design
- Rett syndrome Phase 3 planned for approximately 170 participants, with FDA request to add pediatric patients
- Fragile X IND submission expected in September, while outstanding Q2 and Q3 Form 10-Q filings remain a Nasdaq compliance issue
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANAVEX LIFE SCIENCES CORP. 8-K filings
Get the next AVXL 8-K as it lands
Follow AVXL for push alerts, or ask the research agent what this filing means.